CN104073473A - PCV2 virus-like particles as well as preparation method thereof and splitting and VLP assembly buffer liquor - Google Patents
PCV2 virus-like particles as well as preparation method thereof and splitting and VLP assembly buffer liquor Download PDFInfo
- Publication number
- CN104073473A CN104073473A CN201410145870.8A CN201410145870A CN104073473A CN 104073473 A CN104073473 A CN 104073473A CN 201410145870 A CN201410145870 A CN 201410145870A CN 104073473 A CN104073473 A CN 104073473A
- Authority
- CN
- China
- Prior art keywords
- pcv2
- virus
- preparation
- pcv2 virus
- particle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001673669 Porcine circovirus 2 Species 0.000 title claims abstract description 71
- 239000002245 particle Substances 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 239000000872 buffer Substances 0.000 title claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 49
- 108090001074 Nucleocapsid Proteins Proteins 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 16
- 230000009465 prokaryotic expression Effects 0.000 claims abstract description 12
- 241000588724 Escherichia coli Species 0.000 claims abstract description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 32
- 239000012530 fluid Substances 0.000 claims description 23
- 238000005336 cracking Methods 0.000 claims description 22
- 238000013016 damping Methods 0.000 claims description 22
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 19
- 239000006228 supernatant Substances 0.000 claims description 19
- 239000013612 plasmid Substances 0.000 claims description 18
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 claims description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 12
- 238000001556 precipitation Methods 0.000 claims description 12
- 241000894006 Bacteria Species 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 10
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 claims description 8
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 8
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 claims description 8
- 108010052968 leupeptin Proteins 0.000 claims description 8
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 8
- 239000011347 resin Substances 0.000 claims description 8
- 229920005989 resin Polymers 0.000 claims description 8
- 206010010254 Concussion Diseases 0.000 claims description 7
- 230000001580 bacterial effect Effects 0.000 claims description 7
- 230000015556 catabolic process Effects 0.000 claims description 7
- 230000009514 concussion Effects 0.000 claims description 7
- 238000006731 degradation reaction Methods 0.000 claims description 7
- 239000006166 lysate Substances 0.000 claims description 7
- 108020004705 Codon Proteins 0.000 claims description 6
- 230000000968 intestinal effect Effects 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 239000013613 expression plasmid Substances 0.000 claims description 5
- 235000011187 glycerol Nutrition 0.000 claims description 5
- 239000007983 Tris buffer Substances 0.000 claims description 4
- 229920004890 Triton X-100 Polymers 0.000 claims description 4
- 239000013504 Triton X-100 Substances 0.000 claims description 4
- 238000000502 dialysis Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 claims description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 4
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000004606 Fillers/Extenders Substances 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 238000011049 filling Methods 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 241000700605 Viruses Species 0.000 abstract description 22
- 230000014509 gene expression Effects 0.000 abstract description 22
- 229940031626 subunit vaccine Drugs 0.000 abstract description 8
- 230000005847 immunogenicity Effects 0.000 abstract description 6
- 238000005457 optimization Methods 0.000 abstract description 6
- 238000013461 design Methods 0.000 abstract description 2
- 241000202347 Porcine circovirus Species 0.000 abstract 1
- 238000007796 conventional method Methods 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 22
- 229960005486 vaccine Drugs 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 19
- 241000282898 Sus scrofa Species 0.000 description 15
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 9
- 238000011161 development Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000004321 preservation Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 241000701806 Human papillomavirus Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000012723 sample buffer Substances 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 101150044789 Cap gene Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000009849 deactivation Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 101710159752 Poly(3-hydroxyalkanoate) polymerase subunit PhaE Proteins 0.000 description 2
- 101100382437 Porcine circovirus 2 Cap gene Proteins 0.000 description 2
- 101000984477 Porcine circovirus 2 Capsid protein Proteins 0.000 description 2
- 101710130262 Probable Vpr-like protein Proteins 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 241000710914 Totivirus Species 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 150000002460 imidazoles Chemical class 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 239000013595 supernatant sample Substances 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- VADKRMSMGWJZCF-UHFFFAOYSA-N 2-bromophenol Chemical compound OC1=CC=CC=C1Br VADKRMSMGWJZCF-UHFFFAOYSA-N 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 102100038353 Gremlin-2 Human genes 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000641175 Human papillomavirus type 18 Major capsid protein L1 Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 101001032860 Mus musculus Gremlin-2 Proteins 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000000937 inactivator Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 208000028489 postweaning multisystemic wasting syndrome Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses PCV2 virus-like particles as well as a preparation method thereof and splitting and VLP assembly buffer liquor. Based on an autonomous optimization design, a PCV2 nucleocapsid protein gene which is suitable for efficiently expressing in a prokaryotic expression system is artificially synthesized, a full-length gene sequence of the PCV2 nucleocapsid protein gene is expressed by an escherichia coli prokaryotic expression system, and the virus-like particles are efficiently and autonomously assembled by utilizing soluble nucleocapsid protein of the full-length gene sequence under a special condition. An innovation point of the invention is that PCV2VLPs are obtained by utilizing the prokaryotic expression system instead of adopting the conventional method for obtaining VLPs through an eukaryotic expression system; the method is low in cost, simple and efficient, and suitable for large-scale industrial application; moreover, an innovative buffer liquor formula integrating double functions, which not only can promote thallus splitting, but also can be suitable for self-assembling of VLPs, is also applied; besides, the PCV2 virus-like particles obtained in the invention are very highly similar with wild type virus in outline and good in immunogenicity, and can be applied to developing a subunit vaccine and a drug delivery carrier with utilization potentiality of porcine circovirus.
Description
Technical field
The invention belongs to pig circular ring virus vaccine research technical field, be specifically related to a kind of preparation method of PCV2 virus-like particle and the virus-like particle that the method prepares, also have cracking and the VLP assembling damping fluid in method, used.
Background technology
Pig circular ring virus two types (porcine circovirus type2, PCV2) belong to PCV-II section, and diameter is about 17nm, and without cyst membrane, icosahedron is symmetrical, virus covalently closed circular Single-stranded DNA virus.PVC2 causes multisystemic exhaustion syndrome (postweaning multisystemic wasting syndrome after weaned piglet, PMWS) main pathogen, also can cause growing and fattening pigs dermatitis and nephrotic syndrome (porcine dermatis and nephropathy syndrome, PDNS), porcine respiratory syndrome (porcine respiratory disease complex, PRDC), immunosuppression in the syndromes such as the dysentery of newborn piglet and pig body, be difficult to carry out effective pharmacological agent, in addition, the normal concurrent or secondary infection with many cause of diseases of PVC2, Accurate Diagnosis and the effective prevention and control for PVC2, infected have undoubtedly increased difficulty.Wide-scale distribution in the swinery of the world main Swine Production big country before this virales of PVC2, and caused huge financial loss, set up efficient prevention method significant to the comprehensive prevention and control of virus.
Being succeeded in developing in 2006 and starting to apply in North America of pig circular ring virus vaccine, has brought Gospel to global pig industry; In China, first succeeds in registration and first listing in 2010 Bo Linge pig circular ring virus vaccine in 2009, second half 2010 domestic vaccine listing successively.Current subunit vaccine is exactly that the ORF2 fragment of the immunogenic protein of encoding in PCV2 genome is inserted in insect baculovirus, quick by cultivating insect baculovirus, a large amount of acquisition possesses immunogenic PCV2 nucleocapsid protein, then is prepared into vaccine.Mattress lattice as serial in the FLEX of Boehringer Ingelheim animal health (U.S.) company limited are sent out the PCV2 vaccine of pig circular ring virus vaccine and Intervet/Schering Plough animal health company.Also having a kind of is embedded virus deactivation vaccine, and principle is to be replaced into the 0RF2 fragment in non-pathogenic PCVl by the ORF2 fragment of PCV2, has obtained PCVl-PCV2 embedded virus, has the similar immunogenicity with PCV2.The PCV2 vaccine of Pfizer/Fu Dao animal health company development is to have adopted this technology.Totivirus PCV2 inactivated vaccine, due to the difficult cultivation of PCV2, the slow and difficult deactivation of growing, cultivates cost high, and the production cycle is long, so most animals health care company adopts ripe molecular biotechnology to produce subunit vaccine.Only have abroad at present Cimmeria animal health company to produce inactivated virus vaccine, be applicable to sow immunity.Chartered domestic PCV-II vaccine is inactivated virus vaccine." round gram clear " being developed with SH strain by LG strain for the veterinary institute of Harbin, Agricultural University Of Nanjing respectively for 2010.By Harbin Wei Ke biotechnology development company, Shanghai Hai Li biologics company limited, produce porcine circovirus 2 type LG strain inactivated virus vaccine " circle Bi Jing "; By Luoyang Pulaike Biological Engineering Co., Ltd., Jiangsu Nannong High Science Co., Ltd, produce porcine circovirus 2 type SH strain inactivated virus vaccine, 2011 Beijing great Bei agriculture groups develop " Zhu Huantai ".The viral level approximately 10 of above totivirus culture before deactivation
5.5-6.0tCID
50/ mL.The inactivator of application is formaldehyde solution (formalin).Applying in the world PK-15 passage cell cultivates the high-content of PCV2 and is difficult to surpass 10
3.5tCID
50/ mL, and domestic application microcarrier cell suspension culture technology makes antigen valence improve more than 100 times.Antigen protein purifying is to reduce the anaphylactoid important ring of vaccine, and domestic vaccine purifying process in urgent need to be improved, to reach without excess impurity albumen.
Chinese Pigs PCV-II vaccine market situation gathers
The immunogenicity of the subunit vaccine of conventional recombinant protein development is poor, be mainly because target protein cannot correctly fold or fully submission to immunity system.Virus-like particle (virus-like particles, VLPs) be not contain the hollow shell structure of viral nucleic acid, many virus structural proteins all have the ability that automatic Composition becomes VLPs, similar to natural virion on morphological structure, have very strong immunogenicity and biologic activity.Because VLPs does not have infectivity as immunogen; good stability, is difficult for inactivation, and it can be by the approach the same with virus infection passs immunocyte; effectively induce the immunity system of body to produce immunoprotection reaction, be applied to new generation vaccine development and there is vast potential for future development.The multiple virus of humans and animals, as the structural protein of human papillomavirus, hepatitis B virus etc. can become virus-like particle by automatic Composition in various expression system.When expressing in prokaryotic expression system, Margaret etc. (2006) research human papillomavirus (HPV) nucleocapsid protein finds, HPV nucleocapsid protein can oneself assembling or is formed virus-like particle (VLPs), and its structure and epitope and natural virion are quite similar.Jiang Bo etc. (2012) are by the 65-71 of coding HPV16L2, and 112-120 epitope Fragments is coupled to AP250 nitrogen end, realize and expressing, and assembling forms VLPs voluntarily, for the research of HPV16L2-AP250VLPs subunit vaccine lays the first stone in prokaryotic cell prokaryocyte.Xie Minghui etc. (2009) adopt escherichia expression system highly-soluble ground to express HPV18-L1 albumen, utilize ion-exchange, hydrophobic interaction chromatography fully to remove the impurity such as nucleic acid and bacterial endotoxin and prepare highly purified albumen, and by assembled in vitro, obtain the HPV18-VLPs with hyperimmunization originality, for the preventative vaccine of development HPV18 is had laid a good foundation.
Insect-baculovirus (Sf9-Baculovirus) expression system is successfully expressed the nucleocapsid protein (Capsid) of PCV2, by density gradient centrifugation, can obtain highly purified PCV2VLPs.The PCV2VLPs subunit vaccine of exploitation, has become the main vaccine kind of current world market on this basis.But, the VLPs that utilizes insect-bacvdovirus system expressing protein to produce with respect to prokaryotic expression system, its complex manufacturing, price is high.Many researchers is utilized intestinal bacteria successful expression PCV2Capsid protein, but it can not be assembled into VLPs in vitro.2013, Yin etc. are fused to PCV2Capsid gene 5' end by Sumo-label, can improve expression and the solubility of PCV2Capsid protein in intestinal bacteria, and PCV2Capsid albumen mass-energy is successfully assembled into VLPs in vitro, but because be expresses after merging with Sumo-label, fused protein after expression and purification need to be used proteolytic cleavage to remove its label, target protein matter just can be assembled into VLPs, thereby production difficulty and cost have been improved, and its VLPs concentration is on the low side, and packaging efficiency is not high.
The present invention passes through gene optimization; adopt innovative PCV2VLPs acquisition methods; simultaneously under the effect of unique damping fluid of the present invention; expression amount and the solubility of PCV2Capsid albumen have been significantly improved; and make the effect of PCV2 virus-like particle assembled in vitro obtain remarkable lifting and perfect; outstanding (Marcekova, Z.et al., 2009Journal of Virological Methods of effect in similar result of study; Yin et al.2010Virology Journal; Wu, PC.et al., 2012, Appl.Microbiol.Biotechnol, etc.), for subunit vaccine and the drug carrier system of downstream research pig circular ring virus provides solid foundation.
Summary of the invention:
The object of this invention is to provide a kind of efficient PCV2 Cap matter and be assembled into the assemble method of PCV2 virus-like particle, and the damping fluid of the particle being assembled into and cracking and VLP assembling use.This assemble method cost is low, it is simple and easy to operate, and significantly improves expression amount and the solubility of PCV2 Cap matter; And make the effect of PCV2 virus-like particle assembled in vitro obtain remarkable lifting and perfect.
The object of the invention is to realize in the following manner:
A preparation method for PCV2 virus-like particle, comprises the following steps successively:
1) choose the degenerate of utilizing codon, the coding PCV2 nucleocapsid protein full-length gene that is suitable for prokaryotic expression of synthetic;
2) the recombinant plasmid transformed intestinal bacteria that the restructuring of gene order and expression plasmid carrier obtained, then add IPTG, and making its concentration in system is 0.1-1mM, and carries out abduction delivering at 25-37 ℃;
3) bacterial precipitation obtaining during by abduction delivering PCV2 nucleocapsid protein is resuspended with cracking and the VLP assembling damping fluid of following formula, supersound process, centrifugal collection supernatant, resin absorption target protein, then wash-out target protein from resin; Described cracking and VLP assembling buffer formulation are: 0.1M NaH
2pO
42H
2o, 0.1M Na
2hPO
4, 20mM Imidazole, 10mM Tris-base, 300mM NaCl, 50mM KCl, 2mM MgCl
2, 0.1M Ammonium citrate, 2%Glycerine, 0.5%Triton X-100,5mM β-Me, 0.1mM PMSF, 1U/mL Leupeptin Protease inhibitor; Wherein Triton X-100, β-Me, PMSF, Leupeptin Protease inhibitor be now with now adding, pH of buffer 8.0, and surplus is pure water.
The described degenerate of utilizing codon, the coding PCV2 nucleocapsid protein full-length gene that is suitable for prokaryotic expression of synthetic is shown in shown in SEQ NO.1.
Step 2) described expression plasmid carrier is pET100_D/TOPO.
Step 2) in, the concentration of IPTG in system is preferably 1mM.
Step 2) abduction delivering temperature is preferably 30 ℃.
Step 3) is resuspended by the ratio of 100mL cracking and assembling damping fluid according to 1 liter of culture of Escherichia coli, standing at least 5 minutes on ice; Then resuspended liquid sample is carried out to ultrasonic degradation at least 10 minutes on ice; The lysate sample that ultrasonic degradation is obtained is carried out centrifugal, is greater than 12000 revs/min, within centrifugal 10-30 minute, collects supernatant for 4 ℃.
In above-mentioned preparation method, by centrifugal obtained supernatant liquor and Ni-NTA HisBind resin-bonded, the volume ratio of upper cleer and peaceful resin extender is 20:1; 4 ℃ of slight concussions were in conjunction with at least 60 minutes; With the rinsing of 10 times of column volume washingss; Finally use elutriant wash-out target protein.
In above-mentioned preparation method, the target protein of wash-out is put into cracking and assemble damping fluid and carry out dialysis overnight.
A PCV2 virus-like particle is to be prepared by above-mentioned method.
The cracking that PCV2 virus-like particle is used and a VLP assembling damping fluid, filling a prescription is: 0.1M NaH
2pO
42H
2o, 0.1M Na
2hPO
4, 20mM Imidazole, 10mM Tris-base, 300mM NaCl, 50mM KCl, 2mM MgCl
2, 0.1M Ammonium citrate, 2%Glycerine, 0.5%Triton X-100,5mM β-Me, 0.1mM PMSF, 1U/mL Leupeptin Protease inhibitor; Wherein Triton X-100, β-Me, PMSF, Leupeptin Protease inhibitor be now with now adding, pH of buffer 8.0, and surplus is pure water.
The Capsid nucleocapsid protein full-length gene of PCV2 wild-type virus is difficult to solubility expression, even be also difficult to great expression by code optimization or additional solubility label, purifying difficulty is larger, and international similar research document almost can not provide gratifying Expression and purification result.The present invention passes through all PCV2 genotype sequence alignments, find Yi Zhu China pig farm the most popular, the aminoacid sequence PCV2b-1B-cap of the most representative PCV2 nucleocapsid protein matter, utilize the degenerate of codon, many of synthetic are suitable for prokaryotic expression, coding PCV2 nucleocapsid protein full-length gene.The gene PCV2b-1B-cap_RCFP(of PCV2 nucleocapsid protein matter that utilizes escherichia coli prokaryotic expression system to filter out a synthetic of high expression level amount refers to shown in SEQ NO.1); By the present invention, in IPTG induction system, expression condition is carried out to series simultaneously and optimize, not only make expression amount greatly promote, increased the solubility of this albumen simultaneously, the sufficient possibility and the high efficiency that provide for the self assembling process of follow-up virus-like particle.Express the intestinal bacteria of PCV2 nucleocapsid protein matter after cracking, in the damping fluid of uniqueness of the present invention, can be assembled into PCV2 virus-like particle, by the mode of simple affinity purification, just can obtain fast a large amount of, high purity PCV2 virus-like particle.
Conventionally VLPs utilizes baculovirus eukaryotic expression system to produce, and then by density gradient centrifugation, carrys out purifying, because cost is high, efficiency is low limits its large-scale application and exploitation.The development of our first passage genetic comparison, gene optimization and synthetic, optimization of Prokaryotic Expression, cracking and assembling damping fluid, that foundation has obtained is a large amount of, the PCV2VLPs of high purity, high-quality, for the extensive industrialization of virus-like particle subunit vaccine of pig annulus two C-type virus Cs, has composed order chapter.
Accompanying drawing explanation
In Fig. 1, A is commercialization engineering plasmid pET100_D/TOPO collection of illustrative plates, and B is total length Cap recombinant plasmid pET-PCV2b-1B-Cap-RCFP collection of illustrative plates used in the present invention;
Fig. 2 is that the total length Cap recombinant plasmid enzyme of Fig. 1 is cut proof diagram; 1, be that total length recombinant plasmid is through Nde I and BamH I double digestion for No. 2, the total length Cap gene fragment expanding for PCR for No. 3;
Fig. 3 is that IPTG induction PCV2 nucleocapsid protein is expressed; 1 is bacterium liquid OD
600before the sample of=1 o'clock results induces, all the other are 30 ℃, sampling after 1mM IPTG induction, 2,3,4 are respectively 3h total protein (comprising soluble protein and insolubility protein), 3h supernatant (soluble protein), 3h precipitates (insolubility protein); 5,6,7 be respectively 6h total protein, 6h supernatant, 6h precipitation; Total length Cap molecular weight of albumen is 32KD, and red arrow is denoted as object Cap protein band;
The transmission electron microscope picture that Fig. 4 obtains while being the cellular lysate of expressing protein of the present invention, shows that solubility supernatant (PCV2capsid albumen) can the autologous VLPs of dressing up particle in cracking and assembling damping fluid;
Fig. 5 is the ni-sepharose purification sample SDS-PAGE analytical results of PCV2 nucleocapsid protein of the present invention; T is the supernatant liquor total protein giving expression to, and F was that the stream after nickel post is worn liquid, the washings that W is certain imidazole concentration, and 1-6 is the albumen after purifying, 10 μ L loadings;
In Fig. 6, A is wild-type PCV2 virus transmission electron microscope picture, and B is the PCV2VLPs transmission electron microscope picture that the present invention obtains;
In Fig. 7, A is wild-type PCV2 virus infection pig renal epithelial cell, Laser Scanning Confocal Microscope image; B is that PCV2VLPs prepared by the present invention infects pig renal epithelial cell, Laser Scanning Confocal Microscope image, and experiment antibody is the serum obtaining after injected in mice VLPs.The PCV2VLPs that the present invention obtains as can be seen from Figure has the infectivity same with wild-type virus, and the validity of antibody shows that VLP has good immunogenicity simultaneously.
Embodiment
Below in conjunction with concrete example, confirm to test to be intended to further illustrate the present invention, and unrestricted the present invention.
Experimental procedure
1.PCV2b-1B-cap synthetic and construction of recombinant plasmid
Because wild type full-length Cap albumen is difficult to express, so we first pass through all PCV2 genotype sequence alignments, find out the total length Cap gene order that tool represents type, then according to the Preference of e. coli codon, optimize and synthesized a PCV2 Nucleocapsid Protein Gene type sequence PCV2b-1B-cap.By PCV2b-1B-cap and expression plasmid pET100_D/TOPO(American I nvitrogen company) carrier restructuring formation pET-PCV2b-1B-cap_RCFP recombinant plasmid, insertion point is in the TOPO district of engineering plasmid, restriction enzyme site N end is Nde I, and C end is BamH I.
2.pET-PCV2b-1B-cap_RCFP recombinant plasmid transformed e. coli bl21
1) get 100 μ L BL21(DE3) competence is placed on ice and thaws, and adds the about 10ng of 1 μ L() recombinant plasmid, and with rifle head stirring and evenly mixing gently.Competence after mixing is placed in 30 minutes on ice.
2) be statically placed in heat shock 60s in 42 ℃ of water-baths.Forward fast in ice bath cooling 1-2 minute to.The SOC substratum that adds 900 μ L, mixes.37 ℃, 230rpm concussion is cultivated 45 minutes.
3) getting 50 μ L conversion fluids is applied to and contains 100 μ g/mL Amp
+lB culture plate in, be inverted to cultivate 12-16h for 37 ℃.
The condition that 3.IPTG induction PCV2 nucleocapsid protein is expressed is explored
1) random picking mono-clonal is inoculated in 10mL and contains 100 μ g/mL Amp
+lB nutrient solution in, 37 ℃, the 230rpm concussion amplification cultivation of spending the night.
2) the bacterium liquid of drawing 100 μ L incubated overnight by 1:100 contains 100 μ g/mL Amp to 10mL
+lB nutrient solution in, 37 ℃, 250rpm concussion is cultured to OD
600reach 1.0.
3) draw 1mL bacterium liquid, centrifugal 1 minute of 10,000g, removes supernatant, adds the abundant suspension cell precipitation of 200 μ L2xSDS-PAGE sample buffer, immediately-20 ℃ of preservations of bacterial precipitation (negative control sample).
4) temperature is adjusted into 30 ℃, adding IPTG to make IPTG concentration in system is 1mM, after abduction delivering, at 3h, 6h, draw respectively 2mL bacterium liquid, divide and be filled to 4 1.5mL centrifuge tubes (3h-1,3h-2,6h-1,6h-2), 10,000r/ minute centrifugal 2 minutes, remove supernatant, bacterial precipitation (protein sample)-20 ℃ preservation.
4.PCV2 nucleocapsid protein soluble analysis
1) bacterial precipitation (3h-1 obtaining during by above-mentioned the 3rd abduction delivering 3h, 6h, 6h-1) with resuspended in 500 μ L cracking of the present invention and assembling damping fluid, (3h-2,6h-2) with resuspended in 400 μ L cracking of the present invention and assembling damping fluid, standing and reacting is 10 minutes on ice, and then sample carries out ultrasonic degradation, ultrasonic 5s, stop 5s, 15% amplitude ultrasonic 10 minutes altogether (operation on ice).
2) by the 3h-2 after ultrasonic, 6h-2 lysate sample adds 100 μ L5 * SDS-PAGE sample buffer, and precipitation is blown and beaten for several times fully to dissolve.Boil 5 minutes.The total protein sample of this sample for expressing, analyzes for SDS-PAGE.
3) sample 3h-1,6h-1,4 ℃ are centrifugal 18,000g, 10 minutes.Supernatant liquor 450 μ L are transferred to new aseptic centrifuge tube, are placed on ice and preserve.Get 50 μ L supernatant samples and carry out electron microscopic observation; 400 μ L samples add 100 μ L5 * SDS-PAGE sample buffer and boil 5 minutes, and this sample is solubility supernatant sample, as follow-up SDS-PAGE electrophoretic analysis.
4) by step 3), sample 3h-1, the cell precipitation after 6h-1 is centrifugal partly uses 1mL PBS damping fluid resuspended, 18,000g4 ℃ centrifugal 5 minutes, remove supernatant liquor (object: the soluble proteome removing in precipitation divides).Add 500 μ L1 * SDS-PAGE sample buffer, precipitation is blown and beaten for several times fully to dissolve.Boil 5 minutes.Precipitate resuspended liquid and carry out ultrasonic degradation, ultrasonic 5s, stops 5s, and 15% amplitude ultrasonic 10 minutes altogether, guarantees not thickness of sample.This sample is insolubility protein sample, is used as follow-up SDS-PAGE electrophoretic analysis.
6) sample of preserving in above-mentioned steps is carried out to SDS-PAGE electrophoretic analysis, check expression and the solubility situation of target protein.
The extensive abduction delivering of 5.PCV2 nucleocapsid protein
1) random picking mono-clonal is inoculated in 10mL and contains 100 μ g/mL Amp
+lB nutrient solution in, 37 ℃, the 230rpm concussion amplification cultivation of spending the night.
2) the bacterium liquid of drawing 1mL incubated overnight by 1:1000 contains 100 μ g/mL Amp to 1L
+lB nutrient solution in, 37 ℃, 250rpm concussion is cultured to OD
600reach 1.0.
3) adding IPTG to make IPTG concentration in system is 1mM, 30 ℃, and 250rpm abduction delivering 6h, centrifugal 10 minutes of 8,000g, removes supernatant, bacterial precipitation-20 ℃ preservation.
The ni-sepharose purification of 6.PCV2 nucleocapsid protein
1) get 20mL cracking of the present invention and standing the reaction 10 minutes of the assembling resuspended bacterial precipitation of damping fluid (200mL culture) on ice.
2) sample is carried out to ultrasonic degradation, 30% amplitude, ultrasonic 5s, stops 5s, ultrasonic 10 minutes altogether, guarantees not thickness of sample.Centrifugal 20 minutes of 18,000g, 4 ℃, draw supernatant liquor and be transferred to new aseptic centrifuge tube, is placed on ice and preserves.
3) supernatant liquor is joined in 2mL Ni-NTA HisBind resin, 4 ℃ slightly shake in conjunction with 60 minutes.
4) will be transferred in pillar containing Packed supernatant, stream will be worn to liquid (flow though) after pillar once, and collect stream and wear liquid preservation for SDS-PAGE electrophoretic analysis.
5) with 5 times of column volume washingss (wash buffer) rinsing.
6) by 10 times of packing volume, add elutriant (elution buffer) wash-out target protein, with 2mL centrifuge tube, collect every pipe and collect 2mL, 4 ℃ or preservation on ice.
7) with a large amount of PBS, rinse filler, last equal-volume adds 20% ethanol to preserve, and preserves resin extender.
8) sample of above-mentioned steps being collected is got small part and is added SDS sample buffer, boils, and carries out then SDS-PAGE analyzing proteins purifying situation of protein denaturation processing.
The assembling of 7.PCV2 virus-like particle
1) albumen of step 6 purifying is carried out to determination of protein concentration, BCA method or ultraviolet spectrophotometry.
2) protein sample that concentration is greater than to 0.5mg/mL is transferred in dialysis tubing, puts into cracking and assembling damping fluid carries out dialysis overnight, and second day carries out electron microscopic observation.
8.PCV2 virus-like particle immune mouse
By the VLP particle immune mouse of results.
9.VLP infected cell immunofluorescence experiment
VLPs infects PK15 pig renal epithelial cell, and the serum that the mouse from immune is obtained with it carries out cellular immunofluorescence experiment as antibody.
Experimental result
The design of 1.PCV2b-1B-cap-RCFP gene and synthetic
Pig gyrate virus II type involved in the present invention (PCV2) nucleocapsid protein full-length gene PCV2-1B-cap-RCFP, for this laboratory is through production optimization, is suitable for solution expression with high efficiency in intestinal bacteria prokaryotic cell prokaryocyte.PCV2b-1B-cap-RCFP total length cap gene nucleotide series SEQ NO.1 is as follows:
ATGACCTATCCGCGTCGTCGTTATCGCCGCCGCCGCCATCGCCCGCGTAGTCATCTGGGTCAGATCCTG
CGTCGCCGTCCGTGGCTGGTTCATCCGCGCCACCGTTACCGTTGGCGCCGTAAAAACGGTATTTTTAAT
ACGCGTCTGAGTCGCACGTTCGGCTATACCATCAAACGTACCACGGTGAAGACCCCGTCCTGGGCGG
TTGATATGATGCGCTTTAACATTAATGACTTCCTGCCGCCGGGCGGTGGCAGCAACCCGCGTTCTGTTC
CGTTTGAATATTACCGTATTCGCAAAGTGAAGGTTGAATTCTGGCCGTGCTCTCCGATCACCCAAGGT
GATCGCGGTGTTGGCAGCTCTGCAGTCATTCTGGATGACAACTTTGTCACCAAAGCGACGGCCCTGA
CCTATGATCCGTACGTGAATTATAGTTCCCGTCATACCATCACGCAGCCGTTTTCATACCACTCGCGCTA
TTTCACGCCGAAACCGGTTCTGGATTCAACCATTGACTATTTTCAACCGAACAATAAGCGTAACCAGC
TGTGGCTGCGCCTGCAAACGGCAGGCAATGTCGATCACGTGGGTCTGGGCACCGCTTTCGAAAACTC
GATTTACGACCAGGAATATAATATCCGTGTCACGATGTATGTCCAGTTCCGTGAATTTAACCTGAAAGA
CCCGCCGCTGAATCCGTAATAA
PCV2b-1B-Cap-RCFP aminoacid sequence SEQ NO.2 is as follows:
MTYPRRRYRRRRHRPRSHLGQILRRRPWLVHPRHRYRWRRKNGIFNTRLSRTFGYTIKRTTVKTPSWAVD
MMRFNINDFLPPGGGSNPRSVPFEYYRIRKVKVEFWPCSPITQGDRGVGSSAVILDDNFVTKATALTYDPY
VNYSSRHTITQPFSYHSRYFTPKPVLDSTIDYFQPNNKRNQLWLRLQTAGNVDHVGLGTAFENSIYDQEY
NIRVTMYVQFREFNLKDPPLNPMTYPRRRYRRRRHRPRSHLGQILRRRPWLVHPRHRYRWRRK
233 amino acid; The about 27.85KD of molecular weight; Iso-electric point 10.82.
2. the structure of recombinant plasmid
The method that PCV2b-1B-Cap-RCFP is cut to connection by enzyme is cloned into pET100_D/TOPO carrier (see Fig. 1, a is original engineering plasmid pET100_D/TOPO, and b is recombinant plasmid pET-PCV2b-1B-Cap-RCFP).Plasmid is cut evaluation through enzyme, and size meets expection, and the result of order-checking is 100% coupling also.As shown in Figure 2, after PCV2 nucleocapsid protein Cap total length recombinant plasmid double digestion, fragment meets object size, shows that plasmid recombinates successfully.
The expression of 3.PCV2 nucleocapsid protein
As Fig. 3, the recombinant plasmid of PCV2 nucleocapsid protein full-length gene order can be under experimental technique of the present invention successful solubility expression and there is good expression amount.
4. solubility supernatant electronic microscope photos
As Fig. 4, by electron microscopic observation, in cracking and assembling damping fluid, can autologously be assembled into VLPs.
5. total length VLPs ni-sepharose purification, result details are shown in Fig. 5.
The graininess electronic microscope photos of 6.VLPs
PCV2 nucleocapsid protein VLPs is rendered as icosahedron shape hollow bead homogeneous, diameter 20nm left and right in the visual field, and size is close with form natural viral particle, and details are shown in Fig. 6.
7.VLP infected cell immunofluorescence experiment
As Fig. 7, by immunofluorescence experiment, illustrate that VLPs prepared by the present invention has the infectivity same with wild-type virus, antibody is the serum obtaining after injected in mice VLP, proves that VLP has good immunogenicity.
The inventive example confirms to test related reagent formula
Cracking and assembling damping fluid, MW represents molecular weight:
pH8.0
Wash?Buffer:pH8.0
| WC | Items |
| 50mM | NaH 2PO 4·2H 2O（MW.156.01） |
| 20mM | Imidazole（MW.68.08） |
| 500mM | NaCl（MW.58.44） |
Elution?buffer:pH6.0
| WC | Items |
| 300mM | Imidazole（MW.68.08） |
| 300mM | NaCl（MW.58.44） |
5×SDS-PAGE?sample?buffer
| WC | Items |
| 225mM | Tris-HCl（pH6.8） |
| 50% | Glycerine |
| 5% | SDS |
| 0.05% | bromophenol?blue |
| 25% | β-Me |
The contrast of experiment correlated results
Research Literature PCV2 nucleocapsid protein of the same type obtains experiment lysate formula used
Through experimental test, the lysate purifying PCV2 total length Cap albumen of applying above-mentioned several formulas can not reach the same texts of the present invention's formula, and main manifestations is that albumen solubility is not high, and major part is inclusion body protein; PCV2 total length Cap albumen can not correctly assembling in above-mentioned several lysate formulas in addition.
Claims (10)
1. a preparation method for PCV2 virus-like particle, is characterized in that, comprises the following steps successively:
1) choose the degenerate of utilizing codon, the coding PCV2 nucleocapsid protein full-length gene that is suitable for prokaryotic expression of synthetic;
2) the recombinant plasmid transformed intestinal bacteria that the restructuring of gene order and expression plasmid carrier obtained, then add IPTG, and making its concentration in system is 0.1-1mM, and carries out abduction delivering at 25-37 ℃;
3) bacterial precipitation obtaining during by abduction delivering PCV2 nucleocapsid protein is resuspended with cracking and the VLP assembling damping fluid of following formula, supersound process, centrifugal collection supernatant, resin absorption target protein, then wash-out target protein from resin; Described cracking and VLP assembling buffer formulation are: 0.1M NaH
2pO
42H
2o, 0.1M Na
2hPO
4, 20mM Imidazole, 10mM Tris-base, 300mM NaCl, 50mM KCl, 2mM MgCl
2, 0.1M Ammonium citrate, 2%Glycerine, 0.5%Triton X-100,5mM β-Me, 0.1mM PMSF, 1U/mL Leupeptin Protease inhibitor; Wherein Triton X-100, β-Me, PMSF, Leupeptin Protease inhibitor be now with now adding, pH of buffer 8.0, and surplus is pure water.
2. the preparation method of PCV2 virus-like particle according to claim 1, is characterized in that, the described degenerate of utilizing codon, and the coding PCV2 nucleocapsid protein full-length gene that is suitable for prokaryotic expression of synthetic is shown in shown in SEQ NO.1.
3. the preparation method of PCV2 virus-like particle according to claim 1, is characterized in that step 2) described expression plasmid carrier is pET100_D/TOPO.
4. the preparation method of PCV2 virus-like particle according to claim 1, is characterized in that step 2) in the concentration of IPTG in system be 1mM.
5. the preparation method of PCV2 virus-like particle according to claim 1, is characterized in that step 2) abduction delivering temperature be 30 ℃.
6. the preparation method of PCV2 virus-like particle according to claim 1, is characterized in that, step 3) is resuspended by the ratio of 100mL cracking and assembling damping fluid according to 1 liter of culture of Escherichia coli, standing at least 5 minutes on ice; Then resuspended liquid sample is carried out to ultrasonic degradation at least 10 minutes on ice; The lysate sample that ultrasonic degradation is obtained is carried out centrifugal, is greater than 12000 revs/min, within centrifugal 10-30 minute, collects supernatant for 4 ℃.
7. the preparation method of PCV2 virus-like particle according to claim 1, is characterized in that, by centrifugal obtained supernatant liquor and Ni-NTA HisBind resin-bonded, the volume ratio of upper cleer and peaceful resin extender is 20:1; 4 ℃ of slight concussions were in conjunction with at least 60 minutes; With the rinsing of 10 times of column volume washingss; Finally use elutriant wash-out target protein.
8. the preparation method of PCV2 virus-like particle according to claim 1, is characterized in that, the target protein of wash-out is put into cracking and assemble damping fluid and carry out dialysis overnight.
9. a PCV2 virus-like particle, is characterized in that, is to be prepared by the method described in claim 1-8 any one.
10. PCV2 virus-like particle cracking and a VLP assembling damping fluid used, is characterized in that, filling a prescription is: 0.1M NaH
2pO
42H
2o, 0.1M Na
2hPO
4, 20mM Imidazole, 10mM Tris-base, 300mM NaCl, 50mM KCl, 2mM MgCl
2, 0.1M Ammonium citrate, 2%Glycerine, 0.5%Triton X-100,5mM β-Me, 0.1mM PMSF, 1U/mL Leupeptin Protease inhibitor; Wherein Triton X-100, β-Me, PMSF, Leupeptin Protease inhibitor be now with now adding, pH of buffer 8.0, and surplus is pure water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410145870.8A CN104073473B (en) | 2014-04-11 | 2014-04-11 | A kind of PCV2 virus-like particle and preparation method thereof assembles damping fluid with cracking and VLP |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410145870.8A CN104073473B (en) | 2014-04-11 | 2014-04-11 | A kind of PCV2 virus-like particle and preparation method thereof assembles damping fluid with cracking and VLP |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104073473A true CN104073473A (en) | 2014-10-01 |
| CN104073473B CN104073473B (en) | 2016-03-23 |
Family
ID=51595079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410145870.8A Active CN104073473B (en) | 2014-04-11 | 2014-04-11 | A kind of PCV2 virus-like particle and preparation method thereof assembles damping fluid with cracking and VLP |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104073473B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104498439A (en) * | 2014-11-28 | 2015-04-08 | 湖南农业大学 | Hybridoma cell, PCV2 monoclonal antibody and application thereof |
| CN107164339A (en) * | 2017-06-14 | 2017-09-15 | 中国科学院武汉病毒研究所 | A kind of method in protein nano cage interior packing allogenic material |
| CN107245477A (en) * | 2017-06-06 | 2017-10-13 | 广东海大畜牧兽医研究院有限公司 | A kind of preparation method of 2 porcine circovirus virus-like particle and the virus-like particle obtained by this method |
| CN108355131A (en) * | 2018-02-12 | 2018-08-03 | 江苏南农高科技股份有限公司 | 2 porcine circovirus d virus-like particle vaccines and preparation method thereof |
| CN108588154A (en) * | 2018-04-23 | 2018-09-28 | 武汉中拓康明生物科技有限公司 | A method of non-VLPs albumen in heat treatment removal PCV2 VLPs |
| CN108611359A (en) * | 2018-05-04 | 2018-10-02 | 武汉科前生物股份有限公司 | The preparation method and applications of 3 virus-like particle of pig circular ring virus |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103451196A (en) * | 2013-09-13 | 2013-12-18 | 江苏省农业科学院 | Codon optimized porcine circovirus type 2 Cap protein coding gene and application thereof |
-
2014
- 2014-04-11 CN CN201410145870.8A patent/CN104073473B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103451196A (en) * | 2013-09-13 | 2013-12-18 | 江苏省农业科学院 | Codon optimized porcine circovirus type 2 Cap protein coding gene and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| PEI-CHING WU等: "Characterization of porcine circovirus type 2 (PCV2) capsid particle assembly and its application to virus-like particle vaccine development", 《APPL MICROBIOL BIOTECHNOL》 * |
| SHUANGHUI YIN等: "Self-assembly of virus-like particles of porcine circovirus type 2 capsid protein expressed from Escherichia coli", 《VIROLOGY JOURNAL》 * |
| ZUZANA MARCEKOVA等: "Heterologous expression of full-length capsid protein of porcine circovirus 2 in Escherichia coli and its potential use for detection of antibodies", 《JOURNAL OF VIROLOGICAL METHODS》 * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104498439A (en) * | 2014-11-28 | 2015-04-08 | 湖南农业大学 | Hybridoma cell, PCV2 monoclonal antibody and application thereof |
| CN104498439B (en) * | 2014-11-28 | 2017-10-03 | 湖南农业大学 | Hybridoma, PCV2 monoclonal antibodies and its application |
| CN107245477A (en) * | 2017-06-06 | 2017-10-13 | 广东海大畜牧兽医研究院有限公司 | A kind of preparation method of 2 porcine circovirus virus-like particle and the virus-like particle obtained by this method |
| CN107245477B (en) * | 2017-06-06 | 2020-06-30 | 广东海大畜牧兽医研究院有限公司 | Preparation method of porcine circovirus type 2 virus-like particles and virus-like particles obtained by method |
| CN107164339A (en) * | 2017-06-14 | 2017-09-15 | 中国科学院武汉病毒研究所 | A kind of method in protein nano cage interior packing allogenic material |
| CN108355131A (en) * | 2018-02-12 | 2018-08-03 | 江苏南农高科技股份有限公司 | 2 porcine circovirus d virus-like particle vaccines and preparation method thereof |
| CN108588154A (en) * | 2018-04-23 | 2018-09-28 | 武汉中拓康明生物科技有限公司 | A method of non-VLPs albumen in heat treatment removal PCV2 VLPs |
| CN108588154B (en) * | 2018-04-23 | 2021-05-18 | 杨凌凯瑞生物科技有限公司 | Method for removing non-VLPs proteins in PCV2 VLPs through heat treatment |
| CN108611359A (en) * | 2018-05-04 | 2018-10-02 | 武汉科前生物股份有限公司 | The preparation method and applications of 3 virus-like particle of pig circular ring virus |
| CN108611359B (en) * | 2018-05-04 | 2021-11-19 | 武汉科前生物股份有限公司 | Preparation method and application of porcine circovirus type 3 virus-like particles |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104073473B (en) | 2016-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104073473B (en) | A kind of PCV2 virus-like particle and preparation method thereof assembles damping fluid with cracking and VLP | |
| CN104404074B (en) | The preparation method of hoof-and-mouth disease virus capsid protein series connection coexpression and virus-like particle | |
| Xu et al. | Self-assembly of virus-like particles of canine parvovirus capsid protein expressed from Escherichia coli and application as virus-like particle vaccine | |
| CN108611359B (en) | Preparation method and application of porcine circovirus type 3 virus-like particles | |
| Norkiene et al. | Production of recombinant VP1-derived virus-like particles from novel human polyomaviruses in yeast | |
| CN108823231A (en) | A kind of 3 type genetic engineering subunit vaccine of pig circular ring virus and preparation method thereof | |
| CN105999255A (en) | Virus-like particle vaccine for PCV2 (porcine circovirus 2) as well as preparation method and application of virus-like particle vaccine | |
| CN106399350A (en) | Porcine circovirus type II virus-like particle vaccine and preparation method thereof | |
| CN103451196A (en) | Codon optimized porcine circovirus type 2 Cap protein coding gene and application thereof | |
| CN104561049A (en) | Recombinant baculovirus expressing porcine parvovirus VP2 protein as well as preparation method and application | |
| CN112011556B (en) | Porcine circovirus 2b and 2d type bivalent virus-like particle vaccine as well as preparation method and application thereof | |
| CN107227311A (en) | Recombination porcine parvovirus like-particles and its preparation method and application | |
| CN105349562B (en) | Express recombinant vector, recombinant bacterium and its application of PPV VP 2 protein | |
| Yang et al. | Investigation of Kluyveromyces marxianus as a novel host for large‐scale production of porcine parvovirus virus‐like particles | |
| CN101570571B (en) | Truncated human papilloma virus 18 type L1 protein | |
| CN107973841A (en) | Preparation method and application of recombinant bovine viral diarrhea virus E2 protein expressed by CHO (Chinese hamster ovary) cell and subunit vaccine | |
| CN113862284B (en) | Gene, virus-like particle, vaccine and preparation and application for encoding recombinant avian influenza virus HA protein | |
| CN103540605A (en) | Capsid protein phage display particle of recombinant II porcine circovirus as well as preparation method and application thereof | |
| CN106478783A (en) | A kind of Porcine Circovirus genetic engineering subunit vaccine and its application | |
| CN110129348A (en) | Efficiently recombinant DNA carrier, application and the vaccine of preparation foot and mouth disease virus sample particle | |
| CN106754981B (en) | Method for preparing gosling plague virus-like particles by using escherichia coli system | |
| WO2018188639A1 (en) | Porcine epidemic diarrhea virus s protein, subunit vaccine thereof, and preparation method for and application of the subunit vaccine | |
| CN104673760B (en) | A kind of purification process of procaryotic cell expression viruslike particle | |
| CN103103205B (en) | Gene for encoding recombinant porcine circovirus type 2 (PCV2) Cap protein and application of gene | |
| CN103059142B (en) | Recombinant protein of antigen to porcine circovirus and antigen to porcine reproductive and respiratory syndrome virus, and preparation method and application of recombinant protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220425 Address after: 410128 room 02, courtyard 78, Donghu sub district office, Furong district, Changsha City, Hunan Province Patentee after: Hunan paizhi Biotechnology Co.,Ltd. Address before: Park Road, Rockville, Maryland, USA, biomedical research institute, purcay Co., Ltd Patentee before: AMERICAN PERCE BIOLOGICAL HIGH-TECH Ltd. Patentee before: Hunan Agricultural University |
|
| TR01 | Transfer of patent right |